Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease

IM Wahba, RH Mak - Clinical journal of the American Society of …, 2007 - journals.lww.com
There is an epidemic of obesity and the metabolic syndrome in the United States and across
the world. Both entities are associated with high mortality, mainly as a result of …

(Patho) physiological significance of the serum-and glucocorticoid-inducible kinase isoforms

F Lang, C Bohmer, M Palmada… - Physiological …, 2006 - journals.physiology.org
The serum-and glucocorticoid-inducible kinase-1 (SGK1) is ubiquitously expressed and
under genomic control by cell stress (including cell shrinkage) and hormones (including …

Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption

YF Guan, C Hao, DR Cha, R Rao, W Lu, DE Kohan… - Nature medicine, 2005 - nature.com
Thiazolidinediones (TZDs) are widely used to treat type 2 diabetes mellitus; however, their
use is complicated by systemic fluid retention. Along the nephron, the pharmacological …

[图书][B] Brenner and Rector's the Kidney

ASL Yu, GM Chertow, VA Luyckx, PA Marsden… - 2020 - doctorlib.org
Sodium (Na+) is the principal osmole in extracellular fluid; as such, the total body content of
Na+ and Cl-, its primary anion, determine the extracellular fluid volume. Renal excretion or …

Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08)

E Erdmann, B Charbonnel, RG Wilcox… - Diabetes …, 2007 - Am Diabetes Assoc
OBJECTIVE—PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive)
enrolled patients with type 2 diabetes and preexisting cardiovascular disease. These …

Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial

M Komajda, JJV McMurray, H Beck-Nielsen… - European heart …, 2010 - academic.oup.com
Aims Thiazolidinediones are insulin sensitizers, and are associated with fluid retention and
increased risk of heart failure (HF) in people with type 2 diabetes. We assessed fatal and …

Safety issues and prospects for future generations of PPAR modulators

A Rubenstrunk, R Hanf, DW Hum, JC Fruchart… - … et Biophysica Acta (BBA …, 2007 - Elsevier
Because of their wide range of actions on glucose homeostasis, lipid metabolism and
vascular inflammation, peroxisome proliferator-activated receptors (PPARs) are promising …

Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retention

H Zhang, A Zhang, DE Kohan… - Proceedings of the …, 2005 - National Acad Sciences
The peroxisome proliferator-activated receptor subtype γ (PPARγ) ligands, namely the
synthetic insulin-sensitizing thiazolidinedione (TZD) compounds, have demonstrated great …

Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on β-amyloid peptide fibrils

A Lockhart, L Ye, DB Judd, AT Merritt, PN Lowe… - Journal of Biological …, 2005 - ASBMB
Imaging the progression of Alzheimer's disease would greatly facilitate the discovery of
therapeutics, and a wide range of ligands are currently under development for the detection …

Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome

Y Guan - Journal of the American Society of Nephrology, 2004 - journals.lww.com
Peroxisome proliferator-activated receptors (PPAR) are members of the nuclear hormone
receptor superfamily of ligand-activated transcription factors. Three PPAR isoforms …